HEAL Initiative: Opioid Exposure and Effects on Placenta Function, Brain Development, and Neurodevelopmental Outcomes (R21 Basic Experimental Studies with Humans Required) | RFA HD 23 033

Opportunity Information: Apply for RFA HD 23 033

The HEAL Initiative funding opportunity RFA-HD-23-033 is an NIH R21 Exploratory/Developmental Research Grant aimed at early-stage, high-risk, high-reward studies that can open up new directions in understanding how opioid exposure during pregnancy affects the placenta and infant neurodevelopment. The R21 mechanism is designed for projects that are still in the exploratory or conceptual phase, where the work may be risky but has the potential to produce breakthroughs, generate strong preliminary data, or develop new tools, methods, or experimental approaches that could significantly shift the field.

The scientific focus is on identifying and clarifying the fundamental biological and behavioral mechanisms linking prenatal opioid exposure to placenta function, fetal and infant brain development, and neurodevelopmental outcomes from pregnancy through the first year of life. The FOA specifically includes opioid exposure alone or opioid exposure combined with other commonly misused substances, reflecting real-world polysubstance exposure patterns. A central priority is understanding how these exposures influence placental biology (for example, transport functions, inflammatory signaling, endocrine activity, vascular development, and other placental processes) and how downstream effects may shape early brain development and measurable neurodevelopmental trajectories in infants.

What makes this opportunity distinct is the required study design: applications must use experimental designs in humans that prospectively assign participants to conditions, meaning the independent variable is intentionally manipulated rather than simply observed. NIH classifies these projects as Basic Experimental Studies with Humans (BESH). In practice, that means the research must be basic science in intent (mechanism-oriented, fundamental phenomena) while also meeting the NIH definition of a clinical trial because participants are assigned to one or more conditions. The outcomes can be biomedical and/or behavioral, but the emphasis is on advancing foundational knowledge about opioid-related processes during pregnancy and infancy rather than testing treatments for clinical effectiveness.

At the same time, NIH draws a clear boundary around what is not appropriate for this FOA. Projects should not be aimed at producing clinical outcomes or products, such as demonstrating improved health outcomes from an intervention, validating a clinical protocol, or developing a deliverable clinical tool as the main objective. The goal is mechanistic understanding, not clinical efficacy. In addition, applications that are purely observational in humans (for example, cohort studies without prospective assignment) or that include model animal research are directed to the companion announcement RFA-HD-23-031, which is the R21 pathway where clinical trials are not allowed. In other words, applicants need to match the FOA to the design: this one is for experimentally manipulated, prospective human studies that remain basic science in purpose.

Eligibility is broad and includes many standard applicant types such as state, county, city, township, and special district governments; independent school districts; public and state-controlled and private institutions of higher education; federally recognized Native American tribal governments; public housing authorities/Indian housing authorities; Native American tribal organizations other than federally recognized governments; nonprofit organizations with and without 501(c)(3) status; for-profit organizations (other than small businesses) as well as small businesses; and other eligible entities. NIH also highlights additional eligible applicants such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions, Hispanic-serving Institutions, Historically Black Colleges and Universities, Tribally Controlled Colleges and Universities, faith-based or community-based organizations, regional organizations, eligible federal agencies, and U.S. territories or possessions. Foreign institutions (non-U.S. entities) are not eligible to apply, and non-U.S. components of U.S. organizations are not eligible. However, foreign components as defined under the NIH Grants Policy Statement may be allowed, which typically means a U.S. applicant can include certain justified international elements under NIH rules.

Administratively, this is a discretionary grant opportunity administered by the National Institutes of Health under the HEAL (Helping to End Addiction Long-term) Initiative, and it is associated with multiple CFDA numbers (93.242, 93.273, 93.279, 93.853, 93.865). The opportunity was created on 2022-08-29, with an original closing date listed as 2022-12-07. The award ceiling and expected number of awards are not specified in the provided listing, which is common for some NIH announcements where budgets and counts depend on appropriations, program priorities, and application quality.

Overall, the FOA is best read as a targeted call for creative, mechanism-driven human experimental studies that can clarify how opioid exposure during pregnancy affects placental function and early neurodevelopment, especially during the sensitive window spanning gestation through the infant’s first year. The NIH emphasis is on rigorous experimental manipulation in human participants, careful measurement of biomedical and/or behavioral outcomes relevant to placenta and neurodevelopment, and generating foundational insights that can later inform clinical and public health approaches without making clinical efficacy the central endpoint of the R21 project itself.

• The National Institutes of Health in the education, health, income security and social services sector is offering a public funding opportunity titled "HEAL Initiative: Opioid Exposure and Effects on Placenta Function, Brain Development, and Neurodevelopmental Outcomes (R21 Basic Experimental Studies with Humans Required)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.242, 93.273, 93.279, 93.853, 93.865.
• This funding opportunity was created on 2022-08-29.
• Applicants must submit their applications by 2022-12-07. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for RFA HD 23 033

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: